Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(94)
•••
Post by gojotv!on Jun 16, 2021 11:27am
140 Views
Post# 33395284

Cathy Wood's portfolio overweight on disruptive medical tech

Cathy Wood's portfolio overweight on disruptive medical techFor a reason.
The aging population presents unique opportunities for exponential growth in stocks in early detection and curing disease. 
But she most pointedly mentions early detection in this video...
When Q2 numbers come out and Aristotle's initial sales become clear, investors like her with an eye to medical tech will come swarming in.
She's already got Illumina shares, and they can't get their hands on Grail... and the Galieri test doesn't even measure up to the sensitivity and specificity of the gold standard in multi-cancer detection panels... ARISTOTLE!
All the ducks are in a row for StageZero's breakthrough.
Who else can see it?
GLTA won't-be-longs!

https://m.youtube.com/watch?v=kfhgbZBWgBE



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities